Evidence map›Paper›PMID 37727283›Full record

ArticleWorld journal of gastrointestinal pathophysiology2023

Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against

Christopher K Murphy, Michelle M O'Donnell, James W Hegarty, Sarah Schulz, Colin Hill, R Paul Ross, Mary C Rea, Ronald Farquhar, Laurent Chesnel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal pathophysiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Frontiers in microbiology · 2026
    Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christopher K MurphyResearch and Development, Adiso Therapeutics Inc., Concord, MA 01742, United States.
Michelle M O'DonnellAPC Microbiome Ireland, University College Cork, Cork T12 K8AF, Ireland.
James W HegartyTeagasc Food Research Centre, Moorepark Fermoy, Cork P61 C996, Ireland.
Sarah SchulzAPC Microbiome Ireland, University College Cork, Cork T12 K8AF, Ireland.
Colin HillAPC Microbiome Ireland, University College Cork, Cork T12 K8AF, Ireland.
R Paul RossAPC Microbiome Ireland, University College Cork, Cork T12 K8AF, Ireland.
Mary C ReaTeagasc Food Research Centre, Moorepark Fermoy, Cork P61 C996, Ireland.
Ronald FarquharExecutive Leadership Team, Adiso Therapeutics Inc., Concord, MA 01742, United States.
Laurent ChesnelResearch and Development, Adiso Therapeutics Inc., Concord, MA 01742, United States. lchesnel@adisotx.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Centers for Disease Control and Prevention estimate that

aimTo investigate the

methodsTo mimic disruption of the gut microbiota, the mice were exposed to vancomycin prior to dosing with ADS024. For the mouse single-dose study, the recovery of ADS024 was assessed

resultsIn a mouse model of CDI challenge, single daily doses of ADS024 were as efficacious as multiple daily doses in protecting against subsequent challenge by

conclusionOur findings, demonstrating

Indexed as

ADS024Clostridioides difficileClostridioides difficile challenge modelGutMicrobiotaSingle-strain live biotherapeutic product

Identifiers

PMID37727283
PMCPMC10505952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.